Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monitoring Treatment Response With Urine and Serum Metabolome Markers in Patients Treated With Novel Hormone Therapy and Have Either Hormone Sensitive Metastatic Prostate Cancer or Disease Progression on Treatment.

NCT07837063 is registered in ClinicalTrials.gov with The Clatterbridge Cancer Centre NHS Foundation Trust as lead sponsor.

NCT NCT07837063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07837063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Monitoring Treatment Response With Urine and Serum Metabolome Markers in Patients Treated With Novel Hormone Therapy and Have Either Hormone Sensitive Metastatic Prostate Cancer or Disease Progression on Treatment.
Lead sponsor
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase
Observational
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 3, 2030
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, urology